A methodology for selecting superagonists, antagonists and...

G - Physics – 01 – N

Patent

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

G01N 33/68 (2006.01) C07K 14/475 (2006.01) C07K 14/52 (2006.01) G01N 33/566 (2006.01) G01N 33/74 (2006.01)

Patent

CA 2142973

It has been found that the ligands of the group of cytokins similar to Interleukin 6 (IL-6), that is Oncostatin M (OSM), Leukemia Inhibitory Factor (LIF), Ciliary Neurotrophic Factor (CNTF) and Interleukin 11 (IL-11), induce formation of a receptor complex of which the membrane molecule gp 130 is a part. It is thus possible to formulate the hypothesis that two different surfaces of the protein (in this class of hormones), known as site 1 and site 2 bind to two different molecules: site 1 to the specific receptor and site 2 to gp 130. The invention allows the identification of these sites and the isolation of variants having, with respect to the wild hormone, a greater affinity for the specific receptor (superagonists and superantagonists) or affinity for gp 130 reduced or abolished (antagonists and superantagonists). The figure shows the construct pHen.DELTA. hIL-6 and the production of phasmidic particles that can be used to select agonists of Interleukin 6.

Il s'avère que les ligands du groupe de cytokines semblables à l'interleukine 6 (Il-6), à savoir l'oncostatine M (OSM), le facteur inhibant les cellules leucémiques (LIF), le facteur neurotrophique ciliaire (CNTF) et l'interleukine 11 (IL-11), induisent la formation d'un complexe récepteur dont fait partie la molécule de membrane gp 130. Par conséquent, on peut formuler l'hypothèse que deux surfaces différentes de la protéine (dans cette classe d'hormones), appelées site 1 et site 2, se lient à deux molécules différentes: le site 1 se lie au récepteur spécifique et le site 2 à la gp 130. On peut identifier ces sites et isoler des variantes présentant, par rapport à l'hormone sauvage, une plus forte affinité pour le récepteur spécifique (super-agonistes et super-antagonistes) ou une affinité réduite ou nulle pour la gp 130 (antagonistes et super-antagonistes). Le dessin représente la structure pHen DELTA hIL-6 et la production de particules phasmidiques utilisables dans la sélection d'agonistes de l'interleukine 6.

LandOfFree

Say what you really think

Search LandOfFree.com for Canadian inventors and patents. Rate them and share your experience with other people.

Rating

A methodology for selecting superagonists, antagonists and... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with A methodology for selecting superagonists, antagonists and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and A methodology for selecting superagonists, antagonists and... will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFCA-PAI-O-1630625

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.